Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Items 301–400 of 523
Ruzanova, V. S., Proskurina, A. S., Efremov, Y. R., Kirikovich, S. S., Ritter, G. S., Levites, E. V., Долгова, Е. В., Potter, E. A., Babaeva, O. G., Васильевич, С. С., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610180 · Cited by 16
Fatty Acid Mediators in the Tumor Microenvironment
Khadge, S., Sharp, J. G., Thiele, G. M., McGuire, T. R., & Talmadge, J. E. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43093-1_8 · Cited by 14
Викторовна, Т. Т., Васильевич, Б. Е., Aristova, T. A., Ushakova, G., Анатольевна, С. С., Denisova, V. V., & Chernykh, E. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26362 · Cited by 13
It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
Knickmeier, C., Nzeteu, G. A. N., Gibbs, B. F., Hoogwater, F. J. H., Nijkamp, M. W., Bockhorn, M., & Meyer, N. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1495907 · Cited by 13
Schuler, L. A., & Murdoch, F. E. (2021) · Cancers · doi:10.3390/cancers13153725 · Cited by 14
“Myeloid-derived suppressor cells (MDSCs) are heterogeneous immune populations, which can be derived from either the monocytic (mMDSC) or granulocytic (gMDSC or PMN-MDSC) lineages (reviewed in [85]).”
BackgroundHofstee, M. I., Heider, A., Häckel, S., Constant, C., Riool, M., Richards, R. G., Moriarty, T. F., & Zaat, S. A. J. (2021) · Pathogens · doi:10.3390/pathogens10111446 · Cited by 13
Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy
Carelock, M. E., Master, R. P., Kim, M., Jin, Z., Wang, L. A., Maharjan, C. K., Hua, N., De, U., Kolb, R. H., Xiao, Y., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad019 · Cited by 14
“MDSCs sequester crucial metabolic molecules, such as cysteine [27], required for T cell activation and effector function.”
Feng, X., Kim, J., Gonzalez-Matias, G., Aggarwal, N., Manley, A. L., Wu, Z., Solorzano, S., Batchu, S., Gao, S., Chen, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007254 · Cited by 12
Péterlin, P., Debord, C., Eveillard, M., Garnier, A., Bourgeois, A. L., Guillaume, T., Jullien, M., Béné, M. C., & Chevallier, P. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17576 · Cited by 12
Toor, S. M., Khalaf, S., Murshed, K., Nada, M. A., & Elkord, E. (2020) · Journal of Immunology Research · doi:10.1155/2020/9678168 · Cited by 12
“M-MDSCs can be phenotypically distinguished from monocytes by lack of HLA-DR expression, while identi fi cation of other MDSC subsets from di ff erent myeloid populations may require investigating additional markers or con fi rmation on their suppressive abilities [9].”
Lim, C. L., & Lin, V. C. L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08751-2 · Cited by 13
NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer
Ngule, C. M., Shi, R., Ren, X., Jia, H., Oyelami, F., Li, D., Park, Y.-H., Kim, J., Hemati, H., Zhang, Y., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02102-y · Cited by 13
Wu, K., Zheng, X., Yao, Z., Zheng, Z., Huang, W., Mu, X., Sun, F., Liu, Z., & Zheng, J. (2021) · Aging · doi:10.18632/aging.203045 · Cited by 13
“MDSCs, under prevailing research, belong to a sort of cluster in phenotypical heterogeneity of colony featured by their capability to inhibit functions of T lymphocytes and NK cell [31].”
BackgroundGjerstorff, M. F., Traynor, S., Gammelgaard, O. L., Johansen, S., Pedersen, C. B., Ditzel, H. J., & Terp, M. G. (2022) · Cancers · doi:10.3390/cancers14246153 · Cited by 11
“MDSCs represent one of the cell types in the TME that commonly expand in cancer patients and promote advanced tumor progression and T cell suppression in breast cancer [5].”
BackgroundShen, C., Chai, W., Han, J., Zhang, Z., Liu, X., Yang, S., Wang, Y., Wang, D., Wan, F., Fan, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213947 · Cited by 12
Khalil, R. G., Mohammed, D. A., Hamdalla, H. M., & Ahmed, O. M. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156834 · Cited by 11
Rinchai, D., Verzoni, E., Huber, V., Cova, A., Squarcina, P., Cecco, L. D., de Braud, F., Ratta, R., Dugo, M., Lalli, L., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.434 · Cited by 11
“5 9 Hence, gaining detailed information on the type and kinetics of the immunomodulating properties of anticancer drugs would be essential to maximize clinical efficacy when diverse therapeutic strategies are combined with immunotherapy.”
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 12
Hegde, M. M., Sandbhor, P., Aishwarya, J., Gota, V., & Goda, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168454 · Cited by 11
Tumor immune evasion: Systemic immunosuppressive networks beyond the local microenvironment
Yan, C., & Wang, X. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502597122 · Cited by 13
IL-27 regulates NLRP3 inflammasome activation of MDSCs in experimental Sjögren’s syndrome
Xia, X., Long, Q., Zha, J., Jiang, T., Guo, J., Jiang, B., Li, X., & Yao, G. (2023) · International Immunology · doi:10.1093/intimm/dxad037 · Cited by 10
Cuiffo, B., Maxwell, M., Yan, D., Guemiri, R., Boone, A., Bellet, D., Rivest, B., Cardia, J. P., Robert, C., & Fricker, S. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501679 · Cited by 11
Molecular mechanisms governing the differentiation and expansion of myeloid-derived suppressor cells
Wang, K., Wang, X., & Sun, N. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1677201 · Cited by 10
Lee, E. J., Jung, S. P., Park, K. H., & Park, S. I. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113348 · Cited by 10
Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress
Andrés, C., de la Lastra, J. M. P., Juan, C., Plou, F. J., & Pérez‐Lebeña, E. (2023) · Vaccines · doi:10.3390/vaccines11020218 · Cited by 10
“MDSCs are a major obstacle to immunotherapies, as accumulation of MDSC populations in circulating leukocytes and tumor infiltrates has been observed in patients who do not respond to checkpoint inhibitor therapy [11,12].”
BackgroundThe role of myeloid-derived immunosuppressive cells in cardiovascular disease
Li, Q., Mei, A., Qian, H., Min, X., Yang, H., Zhong, J., Li, C., Xu, H. Y., & Chen, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109955 · Cited by 10
Mahanti, K., Saha, J., Sarkar, D., Pramanik, A., Chattopadhyay, N. R., & Bhattacharyya, S. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae013 · Cited by 11
Zhao, J., Wu, M., Li, Z., Su, S., Wen, Y., Zhang, L., & Li, Y. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04020-7 · Cited by 11
“Contrary to hematological malignancies, the majority of solid tumors do not respond obviously to CAR-T cell infusion due to loss of sufficient and typical molecular targets as well as the difficulty of controlling the immunosuppressive microenvironment of tumors [19, 20].”
BackgroundDaSilva, N. A., Barlock, B. J., Guha, P., Ghosh, C. C., Trebino, C. E., Camberg, J. L., Katz, S. C., & Rowley, D. C. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00621-x · Cited by 10
Wang, X., Xu, Z., Liu, Z., Lin, W., Cao, Z., Feng, X., Gao, Y., & He, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.902577 · Cited by 12
“TP53mutation is not only the most common genetic event in NSCLC but also reported to be associated with poor prognosis in cancers, especially non-small cell lung cancer (Ozaki and Nakagawara, 2011).”
BackgroundBohórquez, J. A., Muñoz‐González, S., Pérez‐Simó, M., Revilla, C., Domínguez, J., & Ganges, L. (2019) · Viruses · doi:10.3390/v11090822 · Cited by 10
“In the PBMC from naïve animals, neither 6D10+/CD33+ nor 6D10+/CD11b+ were observed and, therefore, no 6D10+/CD33+/CD11b+ were observed.”
BackgroundResultInfluentialThe Microbiome, Inflammation, and GVHD Axis: The Balance Between the “Gut” and the Bad
Pinzon-Leal, P., Gutiérrez-Barbosa, H., Medina-Moreno, S., & Zapata, J. C. (2025) · Immuno · doi:10.3390/immuno5010010 · Cited by 10
“Although no NLRP3 inhibitors have been approved for use in humans, several molecules—including DFV890, ZYIL1, dapasuntrile, and GDC-2394—are currently being tested in early clinical trials [152–156].”
Yokota, S., Yonezawa, T., Momoi, Y., & Maeda, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110716 · Cited by 10
The Roles of Myeloid-Derived Suppressor Cells in Liver Disease
Zhang, C., Sui, Y., Liu, S., & Yang, M. J. (2024) · Biomedicines · doi:10.3390/biomedicines12020299 · Cited by 9
“…CD14 + CD66b − IL-4R α + ) and PMN-MDSCs (CD15 + CD14 − CD66b + IL-4R α − ) (Figure 1). using biomarkers of CD15, , CD66b, and interleukin/IL-4R α [25]: M-MDSCs (CD15 − CD14 + CD66b − IL-4R α + ) and PMN-MDSCs (CD15 + CD14 − CD66b + IL-4R α − ) (Figure 1) In , both in humans are CD16 − CD33 + HLA…”
Developmental pathways of myeloid-derived suppressor cells in neoplasia
Abrams, S. I. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104261 · Cited by 9
“It is important to point out that studies that report the merit of human MDSCs for prognosis using either cryopreserved preparations, fresh specimens procured several hours post-sample collection or even following processing by density gradient centrifugation may inadvertently underestimate MDSC percentages or numbers…”
BackgroundAnalysis of the Biological Properties of Blood Plasma Protein with GcMAF Functional Activity
Долгова, Е. В., Kirikovich, S. S., Levites, E. V., Ruzanova, V. S., Proskurina, A. S., Ritter, G. S., Taranov, O. S., Анатольевич, В. Н., Ryabicheva, T. G., Leplina, O. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158075 · Cited by 9
Japanese Kampo Medicine Juzentaihoto Enhances Antitumor Immunity in CD1d −/− Mice Lacking NKT Cells
Takaku, S., Shimizu, M., & Takahashi, H. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735419900798 · Cited by 9
Zhang, Q., Yu, T., Tan, H., & Shi, H. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03245-4 · Cited by 8
“** p < 0.01 and *** p < 0.001; n.s., no statistical significance two subtypes, the G-MDSCs and M-MDSCs, according to the diverse expressions of Ly6G and Ly6C [30].”
BackgroundInfluentialOu, Y., Wei, H., Peng, C., Li, J., Wei, K., Zhan, C., & Zhang, Z. (2026) · Cancers · doi:10.3390/cancers18060980 · Cited by 9
Application of chitosan and its derivatives in immunotherapy of malignant neoplasms
Сергеевич, Г. Д., Zhernov, Y. V., Krivtsov, G. G., & Khaitov, M. R. (2020) · Immunologiya · doi:10.33029/0206-4952-2020-41-5-470-478 · Cited by 8
Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection
Shaw, J., Malherbe, S. T., Walzl, G., & du Plessis, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1222911 · Cited by 8
Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review)
Kumar, D., Silva, V. D., & Chaves, N. L. (2024) · Medicine International · doi:10.3892/mi.2024.170 · Cited by 9
“Macrophages and MDSCs are ubiquitous in the majority of solid tumors, driving immune suppression and inflam‑ mation (61). their interaction increases Il‑10 production by MDSCs and decreases Il‑12 production by macrophages, polarizing the immune system toward a type 2 protumor environment (62).”
BackgroundGhosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J. P., Morrissey, M., Fraser, K., Perati, S., Cox, B. F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008837 · Cited by 8
“14 Circulating MDSCs have been associated with a lack of response to CPI, and the presence of LM is an independent predictor of CPI treatment failure in multiple indications.”
Le, P. M., Mattapallil, M. J., Caspi, R. R., Stepp, M. A., & Menko, A. S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.07.021 · Cited by 9
“…Journal of Pathology - ajp.amjpathol.org Figure S10, A and B), consistent with a monocytic myeloid derived suppressor cell (M-MDSC) phenotype, 52 but was barely detectable in the immune cell populations associated with the lens capsule at D35 (Figure 7A and Supplemental Figure S10, A and B).”
Role of Nutrients Regulating Myeloid Derived Suppressor Cells in Cancer: A Scoping Review
Pérez-Peláez, B., Jiménez‐Cortegana, C., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46090549 · Cited by 8
“…are stimulated by proinflammatory molecules, such as IL-6, IL-1 β , IL-17, IL-10, tumor necrosis factor (TNF)- α , or cyclooxygenase (COX)-2, and MDSCs are accumulated in inflammatory sites [6,7] together with other immunosuppressor cells such as regulatory T cells (Treg) or M2 macrophages [8].”
BackgroundDarlyuk‐Saadon, I., Heng, C. K. M., Bai, C. G., Gilad, N., Yu, W., Mok, M. M. H., Wong, W. S. F., & Engelberg, D. (2021) · FEBS Journal · doi:10.1111/febs.15697 · Cited by 8
Breda, L. C. D., Breda, C. N. D. S., Kaihami, G. H., de Almeida, J. R. F., Jannuzzi, G. P., Ferreira, L. G., & de Almeida, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-99847-z · Cited by 8
Márquez-Coello, M., Arjona, M. M. D. O., Martín-Aspas, A., Guerrero-Sánchez, F., Fernández-Gutiérrez, C., & González, J. A. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-48185-2 · Cited by 8
Yoshida, Y., Nagamori, T., Ishibazawa, E., Kobayashi, H., Kure, T., Sakai, H., Takahashi, D., Fujihara, M., & Azuma, H. (2020) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2020.1837866 · Cited by 8
Decreased neutrophil‐mediated bacterial killing in COVID‐19 patients
Nomani, M., Varahram, M., Tabarsi, P., Hashemian, S. M. R., Jamaati, H., Malekmohammad, M., Ghazi, M., Adcock, I. M., & Mortaz, E. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13083 · Cited by 11
Wang, Z., You, T., Cai, C., Su, Q., Cheng, J., Xiao, J., & Duan, X. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c21028 · Cited by 9
The Microbiome and Genitourinary Cancers: A New Frontier
Winslow, T. B., Gupta, S., Vaddaraju, V., Guercio, B. J., & Sahasrabudhe, D. M. (2025) · Cancers · doi:10.3390/cancers17223606 · Cited by 7
Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers
Rabiu, L., Chinn, M., Chen, F., Yerkinkazhina, Y., Tian, Y., & Zhu, W. (2026) · Cancer Science · doi:10.1111/cas.70360 · Cited by 9
“Clinical samples and mouse models demonstrate a strong association between MDSC accumulation and CAC progression, highlighting their role in the transition from colitis to carcinoma [60, 61].”
Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection
Borgna, E., Prochetto, E., Gamba, J. C., Marcipar, I. S., & Cabrera, G. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.09.002 · Cited by 7
Galectin-8 alters immune microenvironment and promotes tumor progression.
Wang, Y., Sun, Y., Li, H., & Xu, J. (2023) · PubMed Central · Cited by 12
Le, P. M., Pal‐Ghosh, S., Stepp, M. A., & Menko, A. S. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.01.006 · Cited by 7
Ezzelarab, M. B., Pérez-Gutiérrez, A., Humar, A., Wijkstrom, M. N., Zahorchak, A. F., Lu-Casto, L., Wang, Y., Wiseman, R. W., Minervini, M. I., & Thomson, A. W. (2019) · Transplant Immunology · doi:10.1016/j.trim.2019.101225 · Cited by 7
“MDSC are a heterogeneous population of immunosuppressive myeloid cells that undergo systemic expansion during inflammatory conditions or cancer [7, 8].”
BackgroundBv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
Benguigui, M., Vorontsova, A., Timaner, M., Levin, S., Haj-Shomaly, J., Deo, A., Rottem, M., Manobla, B., Cooper, T. J., Raviv, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903591 · Cited by 7
Kelly‐Scumpia, K. M., Choi, A. W., Shirazi, R., Bersabe, H., Park, E., Scumpia, P. O., Ochoa, M. T., Yu, J., Ma, F., Pellegrini, M. A., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101050 · Cited by 7
Utariani, A., Sinaga, R., Wardhani, P., & Hardiono, H. (2020) · Bali Journal of Anesthesiology · doi:10.4103/bjoa.bjoa_114_20 · Cited by 7
“Some biomarkers of organ dysfunction occur in patients with sepsis, especially in septic shock, and these markers are related to the severity and mortality of sepsis.[9-13] Thrombocytopenia is a common condition and a multifactorial phenomenon Background: Prompt and reliable identification and risk stratification in s…”
BackgroundCroce, M. V. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.2016800 · Cited by 7
“In fact, MDSC infiltrate the tumor and they constitute highly immune suppressive cells with a significant obstacle to active cancer immunotherapies (75).”
BackgroundGaißler, A., Meldgaard, T. S., Heeke, C., Babaei, S., Tvingsholm, S. A., Bochem, J., Spreuer, J., Amaral, T. M. S., Wagner, N. B., Klein, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906352 · Cited by 7
“Additionally, the presence of regulatory immune cells such as MDSCs, or Tregs that might dampen anti-cancer T cell responses can play a critical role in cancer immunotherapy (42, 43).”
BackgroundNanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
Margulis, K., Honkala, A. T., Kalashnikova, I. V., Noll, S. E., Hill, M. L., Zare, R. N., & Smith, B. R. (2020) · Nanoscale · doi:10.1039/c9nr06494j · Cited by 7
Editorial: Myeloid Derived Suppressor Cells as Disease Modulators
Finn, O. J., & Ochoa, A. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00090 · Cited by 7
Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
Surumbayeva, A., Saiman, Y., & Astsaturov, I. A. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70104 · Cited by 6
“…and TIM3, which limit their antitumor activity (Gao et al. 2022) and enhances the presence of myeloid ‐ derived suppressor cells (MDSCs) and immunosuppressive macrophages, which inhibit T cell responses and foster an immuno-suppressive tumor microenvironment (Ostrand ‐ Rosenberg and Fenselau 2018).”
Recent advances in biomimetic nanodelivery systems for the treatment of glioblastoma
Yuan, Z., Li, J., & Na, Q. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114668 · Cited by 7
Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer
Thankachan, S. V., Jayaraman, V., Datta, L., Apthi, S., Zaman, B. F., Gurunathan, R., Suresh, A., Chandrakesan, P., Vinayagam, R., Kang, S. G., et al. (2025) · Medicina · doi:10.3390/medicina61101776 · Cited by 6
Zhan, Q., Ni, H., Zhou, M., Mao, X., Ouyang, Y., Shi, T., & Li, R. (2025) · Medical Review · doi:10.1515/mr-2025-0035 · Cited by 6
“They can also suppress innate immunity by polarizing macrophages toward a phenotype that promotes tumor growth and inhibits the cytotoxicity of natural killer (NK) cells [99].”
Zhang, X., Zhe, J., Duan, C., Wei, X., He, Z., Shi, C., Yuan, L., Wen, H., Bao, W., & Fan, Q. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02670-0 · Cited by 6
“Treg-derived lEVs containing TGF-β and miR-155 can recruit myeloid-derived suppressor cells (MDSCs), which inhibit effector T cell activity, expand Treg populations, and secrete IL-10 and TGF-β—collec-tively promoting immune tolerance and tumor progression [168].”
Tian, S., Welte, T., Mai, J., Liu, Y., Ramirez, M., & Shen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752934 · Cited by 6
“Since MDSCs tend to infiltrate into the tumor and support tumor growth, theymay also serve as a vector for tumor-orientated transportation of T1 aptamers and hence T1-conjugated therapeutic agents (Ostrand-Rosenberg and Fenselau, 2018).”
BackgroundPavelková, L., Táborská, E., Syding, L. A., Plačková, K., Simonova, E., Hladíková, K., Hensler, M., Laco, J., Koucký, V., Zábrodský, M., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101884 · Cited by 6
“In addition to the chemo-kines listed above, hypoxia-up-regulated expression of VEGF was shown to contribute to accumulation of MDSCs within the TME [35].”
Background[Immune Characteristics of Small Cell Lung Cancer].
Zhu, Y., & Wu, S. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.33 · Cited by 6
Zahorchak, A. F., Pérez-Gutiérrez, A., Ezzelarab, M. B., & Thomson, A. W. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.013 · Cited by 6
“Myeloid-derived suppressor cells (MDSC) comprise a heterogeneous population of regulatory innate immune cells [1, 2] defined initially by their absence of MHC class II and lymphoid-associated antigens.”
BackgroundHuR promotes miRNA-mediated upregulation of NFI-A protein expression in MDSCs during murine sepsis
Bah, I., Alkhateeb, T., Kumbhare, A., Youssef, D. A., Yao, Z. Q., Hawkin, G. A., McCall, C. E., & Gazzar, M. E. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.04.014 · Cited by 6
Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’
Sobottka, B., Lorch, A., Siliņa, K., van den Broek, M. F., & Moch, H. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000864 · Cited by 6
Detection of Circulating and Tissue Myeloid-Derived Suppressor Cells (MDSC) by Flow Cytometry
Sanchez‐Pino, M. D. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1948-3_17 · Cited by 6
Saed, S. M., Abbas, S., Ansary, M. E., Abdelfattah, W., Maurice, K. K., Mohamed, M., & Koptan, D. T. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.1.257 · Cited by 5
“MDSC have been implicated in sustaining progression of numerous malignancies including BC [18].”
BackgroundAngka, L., Tennakoon, G., Cook, D. P., Martel, A. B., Market, M., de Souza, C. T., Cummins, E., Samudio, I. J., Kekre, N. K., Ardolino, M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013304 · Cited by 5
“Therefore, we combined all six patients in our final analysis to increase our statistical power.”
Calvert, R. D., Fleet, J. C., Fournier, P. G. J., Juárez, P., Burcham, G. N., Haverkamp, J. M., Guise, T. A., Ratliff, T. L., & Elzey, B. D. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200079 · Cited by 6
Tan, Z., Chiu, M. S., Yue, M., Kwok, H., Tse, M. H., Yang, W., Chen, B., Yang, D., Zhou, D., Song, Y., et al. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad150 · Cited by 5
KDM6A Lysine Demethylase Directs Epigenetic Polarity of MDSCs during Murine Sepsis
Bah, I., Alkhateeb, T., Youssef, D. A., Yao, Z. Q., McCall, C. E., & Gazzar, M. E. (2021) · Journal of Innate Immunity · doi:10.1159/000517407 · Cited by 5
Hamers, A. A. J., Joshi, S. K., & Pillai, A. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1901044 · Cited by 5
“: MDSCs, expand and recover rapidly after allo-HSCT [29, 30] and can contribute directly to the immunosuppressive tumor microenvironment by dampening T effector cell responses (reviewed in [31, 32]).”
BackgroundAgrati, C., Biasi, S. D., Fidanza, L., Gibellini, L., Nasi, M., Pinti, M., & Cossarizza, A. (2020) · AIDS · doi:10.1097/qad.0000000000002675 · Cited by 6
Gonçalves, B. Ô. P., de Andrade, W. P., Fialho, S. L., & Silva, L. M. (2022) · Acta Histochemica · doi:10.1016/j.acthis.2022.151849 · Cited by 5
The Cancer Immunotherapy Revolution: Mechanistic Insights
Fink, P. J. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1790024 · Cited by 6
Lisowski, C., Stumpf, N. E., Jobin, K., Klaus, D., Eichler, M., Baumgart, A., Babyak, O., Meissner, M., Schröder, A., Neubert, P., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08329-x · Cited by 4
“These effects are largely attributed to pro-or anti-in fl ammatory responses of immune cells like CD8+ T cells [22], Th17 cells [23], or Myeloid-derived suppressor cells (MDSCs) [24].”
Sun, S., Zhao, P., Wang, C., Du, J., Zhang, T., He, X., Zhibo, Z., Li, N., & Zhou, R. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1668583 · Cited by 5
Kanwal, S., To, S. V., Uijen, R. F., Roverts, R., van Cranenbroek, B., van Opzeeland, F. J., Joosten, B., van Saparoea, B. V. D. B., de Jongh, C. E. V. D. G., van Rijssen, E., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01430-y · Cited by 4
“Although MDSCs are typically associated with cancer or chronic in fl ammation 27,28 , their presence following intranasal immunization suggests a potential regulatory role, possibly limiting neutrophil-driven tissue injurywhilepreservingimmunologicalhomeostasis.”
Chen, H., Lin, X., Liu, H., Huang, C., Li, R., Ai, J., Wei, J., & Xiao, S. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.608582 · Cited by 4
Li, T.-T., Lin, C., Chiang, M., He, J.-T., Hung, C., & Hsieh, C. (2023) · Cells · doi:10.3390/cells12111507 · Cited by 4
“…of MDSCs include increasing the expression of reactive oxygen species [11,12], arginase 1, iNOS [9,10], anti-inflammatory cytokines [5], regulatory T cells [13,14], macrophages associated with tumors [15,16], proangiogenic factors [20], and the impairment of natural killer cell cytotoxicity [21].”
Isolation and immunosuppressive functions of myeloid-derived suppressor cell-derived exosomes
Parvin, M., Rashid, M. H., & Arbab, A. S. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.04.006 · Cited by 4
Ruzanova, V. S., Kirikovich, S. S., Levites, E. V., Proskurina, A. S., Долгова, Е. В., Ritter, G. S., Efremov, Y. R., Dubatolova, T. D., Sysoev, A. V., Koleno, D. I., et al. (2024) · Journal of Immunology Research · doi:10.1155/2024/7484490 · Cited by 4
“…28), impeded the correct assessment of the state of tumor-associated CD11b + Ly-6G + /L y-6C + MDSCs not recruited (local) to the resorbing tumor due to the similarity of their super fi cial markers and those expressed by classically activated proin fl ammatory macrophages and neutrophils [12 – 14].”
BackgroundCannabidivarin directly targets the immunosuppressive activity of regulatory myeloid cells in tumors
Steinberg, M., Wyrobnik, I., Procaccia, S., Rosenblum, R., Gelfand, A., Avisidris, S., Novak‐Kotzer, H., & Meiri, D. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118697 · Cited by 3
Wei, Y., Li, R., Xiang, Y., Tong, H., Zhang, Y., Kang, Q., Huang, J., Bao, Y., & Ma, X. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.12.004 · Cited by 4
Hu, X., Wu, H., Liu, T., Liao, Y., Zeng, H., Zou, F., Zhou, J., & Liu, X. (2026) · Journal of International Medical Research · doi:10.1177/03000605251412972 · Cited by 3
“20 Tumor-derived cytokines such as interleukin-6 (IL-6) and granulocyte– macrophage colony-stimulating factor (GM-CSF) promote emergency myelopoiesis and the expansion of myeloid-derived suppressor cells, which dampen antitumor immunity and sustain systemic inflammation.”
Álvarez-Álvarez, A., Fernández, M. G., & Ortiz-Muñoz, G. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.05.001 · Cited by 4
Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Semwal, S., Boukherroub, R., Savvides, S. N., & Bouckaert, J. M. J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210728103524 · Cited by 4
“shown that Myeloid Derived Suppressor Cells (MDSCs), which constitute the majority of the immunosuppressive force alongside TAM and cytokines in the vicinity of the tumour [86].”
BackgroundPlatelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy
Qi, Y., & Mohammadpour, H. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13758 · Cited by 3
Effect of calcitriol on myeloid-derived suppressor cells in physiological aging
Perfilyeva, Y. V., Kali, A., Aben, D. S., Abdusattarova, Y., Lushova, A. V., Ostapchuk, Y. O., Tleulieva, R., Perfilyeva, A. V., Sharipov, K. O., Davlyatshin, T. I., et al. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106768 · Cited by 3
Заботина, Т. Н., Panchuk, I., Tabakov, D., & Захарова, Е. Н. (2020) · Practical oncology · doi:10.31917/2103249 · Cited by 4
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.